Related Experiment Video
Updated: Dec 6, 2025
07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.7K
Biomarkers for hepatocellular cancer
Gurjot Singh1, Eric M Yoshida2, Sahaj Rathi2
1Department of Medicine, University of British Columbia, Vancouver V5Z 1M9, Canada.
World Journal of Hepatology
|October 9, 2020
Summary
Early detection of hepatocellular carcinoma (HCC) is crucial. This review explores biomarkers for diagnosing HCC in at-risk populations and predicting prognosis, aiding in timely and effective treatment strategies.
Area of Science:
- Oncology
- Biomarker Discovery
- Hepatology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
- Late-stage diagnosis limits curative treatment options for HCC.
- Effective biomarkers are needed for early HCC detection, prognosis, and treatment guidance.
Purpose of the Study:
- To review current and emerging biomarkers for hepatocellular carcinoma (HCC).
- To discuss biomarkers for early diagnosis in at-risk populations.
- To explore biomarkers for HCC prognosis and predicting treatment response.
Main Methods:
- Comprehensive literature review of HCC biomarkers.
- Analysis of diagnostic, prognostic, and predictive biomarker studies.
- Synthesis of information on biomarker utility in clinical management.
Main Results:
- Various biomarkers show potential for early HCC detection.
- Biomarkers can aid in risk stratification and predicting disease progression.
- Emerging biomarkers offer promise for personalized HCC therapy.
Conclusions:
- Biomarkers are essential for improving early diagnosis and management of HCC.
- Further research is needed to validate biomarkers for widespread clinical use.
- Biomarker-guided approaches can enhance patient survival and quality of life in HCC.
